Click here to learn more about our clinical development partner, RRD International, and its management team.
Dr. Finn is Chief Executive Officer at RRD International, LLC, and Chairman of ClearPath Development Company LLC, a subsidiary of RRD. Dr. Finn is one of the architects of RRD’s unique product development partnership model and is responsible for the overall direction of the company, creating development strategies, and managing the company’s core product development teams. Dr. Finn has more than 25 years of experience in the research, development, and government regulation of biological and pharmaceutical products covering a wide range of product types and therapeutic indications. Dr. Finn began his career as a Staff Fellow at FDA, Center for Biologics Evaluation and Research. He then entered industry, where he has held senior positions of increasing responsibility in regulatory affairs and product development. Dr. Finn worked for several companies prior to co-founding RRD in 2002, including Lederle-Praxis Biologicals, Miles Pharmaceuticals (Bayer), Genetics Institute, BRI International, and Quintiles. Dr. Finn received a PhD in Biology from Georgetown University and a BS in Zoology from the University of Maryland.
Dr. Alderdice is Vice President of Clinical Operations and Senior Program Leader at RRD International, LLC. Dr. Alderdice works with the Senior Management Team, Quality Assurance, Contracts, and Finance to help assure RRD clinical programs meet or exceed expectations. Dr. Alderdice has more than 30 years of experience in program management and in the planning and implementation of multi-national clinical trials. Prior to RRD he held the titles of Sr. Product Director and Director of Project Management at PRA International, and before that he held positions at Quintiles/BRI, Sigma-Tau Pharmaceuticals, and Bristol Myers Squibb. Dr. Alderdice received a PhD in Pharmacology from the University of Texas Health Science Center, completed his Postdoctoral Fellowship at the University of Connecticut Health Center, and then was Assistant Professor of Pharmacology and Experimental Therapeutics at the LSU Medical Center in New Orleans.
Mr. Johnson has 30 years of experience in the pharmaceutical industry, specializing in all aspects of the development, manufacturing, quality, regulatory, and logistic of biologics, cellular therapies, drugs and devices. Mr. Johnson has a broad range of experience has held senior (up to VP) positions in Development, Quality, Engineering, Manufacturing and Operations at such companies as Bayer, Baxter and Cambrex/Lonza. Mr. Johnson has headed the products divisions for three cellular products companies: Progenitor Cell Therapies, Prima BioMed and Celsis. Mr. Johnson was the Senior Consultant for Biologics/CMC/Operations at Salamandra and Senior Consultant for Technology and Operations at Biologics Consulting Group. He has provided regulatory, quality, manufacturing, project management, corporate operations, and commercialization assistance to such clients as The Gates Foundation (PATH), Prima BioMed, Virxsys, Merck, GSK, LG Bio, Unither Vaccines, Omnia and Serum Institute of India.